<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-9991 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-9991</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-9991</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-170.html">extraction-schema-170</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <p><strong>Paper ID:</strong> paper-261673400</p>
                <p><strong>Paper Title:</strong> <a href="https://assets.cureus.com/uploads/review_article/pdf/180774/20230909-7769-9g93qg.pdf" target="_blank">Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</a></p>
                <p><strong>Paper Abstract:</strong> The hunt for early Alzheimer's disease detection has created cutting-edge diagnostic instruments with enormous promise. This article examines the many facets of these developments, focusing on how they have revolutionised diagnosis and patient outcomes. These tools make it possible to detect tiny brain changes even before they give birth to clinical symptoms by combining cutting-edge biomarkers, neuroimaging methods, and machine-learning algorithms. A significant opportunity for therapies that can slow the course of the disease exists during this early detection stage. Additionally, these cutting-edge techniques improve diagnostic precision, objectivity, and accessibility. Liquid biopsies and blood-based biomarkers provide non-invasive alternatives, filling accessibility gaps in diagnosis. While issues with standardisation, ethics, and data integration continue, collaboration within research, clinical practice, and policy realms fuels positive developments. As technology advances, the way towards better Alzheimer's diagnosis becomes more evident, giving patients and families dealing with this difficult illness fresh hope. The synergy between scientific advancement and compassionate treatment is crucial for improving Alzheimer's disease diagnosis, as this paper emphasises.</p>
                <p><strong>Cost:</strong> 0.02</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e9991.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e9991.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aβ accumulation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta (Aβ) accumulation / plaques</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular accumulation of amyloid-beta peptides (notably Aβ42) forming plaques in the brain, long considered a central pathological hallmark and proposed upstream cause of Alzheimer's disease (AD).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular (protein aggregation)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aggregation and deposition of amyloid-beta peptides (Aβ42, Aβ40) into extracellular plaques in brain tissue; implicated by pathological studies and targeted by amyloid PET tracers and CSF/plasma Aβ assays.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Reviewed literature and longstanding neuropathology link Aβ plaques with AD; decreased CSF Aβ42 and increased brain amyloid on amyloid PET are repeatedly associated with AD and prodromal stages; amyloid PET tracers (PiB, florbetapir, florbetaben, flutemetamol) reliably visualize cortical amyloid burden; CSF Aβ42 and Aβ42/Aβ40 ratios are diagnostic in many cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The review notes that amyloid deposition can be present in persons without dementia (cites meta-analyses) and cites discussions of 'progress and problems' with the amyloid hypothesis, implying that amyloid presence does not always equate to clinical disease and that clinical trials targeting amyloid have had mixed/negative results.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>biomarker / molecular imaging</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Amyloid PET imaging (PiB, florbetapir, florbetaben, flutemetamol) visualizes fibrillar Aβ deposits; CSF Aβ42 (and Aβ42/Aβ40 ratios) measure soluble amyloid-related peptides; plasma Aβ assays (Aβ42, Aβ40 ratios) and high-performance plasma Aβ tests are emerging as blood-based surrogates.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Amyloid PET (table summary): sensitivity ~70–90%, specificity ~90–95% for detecting amyloid deposition; CSF Aβ42 (with t-tau/p-tau) reported combined CSF biomarker sensitivity ~85–90% and specificity ~90–95% for AD vs controls in review; blood-based Aβ assays reported promising performance but lower ranges in the table (blood-based markers sensitivity ~70–80%, specificity ~80–90%). Stage: effective at preclinical and prodromal (early) stages for detecting pathology prior to prominent clinical symptoms.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review of molecular, imaging and clinical studies (systematic search yielding 59 studies)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Varied cohorts and study types across cited literature (as summarized in review); includes asymptomatic older adults, MCI, AD dementia cohorts, and population/meta-analytic studies; this review did not run primary experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Presence of amyloid in cognitively normal individuals (prevalence in non-demented populations) complicates causal inference; the amyloid hypothesis has recognized 'progress and problems' and therapeutic trials targeting amyloid have produced mixed results; PET and some CSF assays are costly or invasive (lumbar puncture); lack of harmonized thresholds and standardization across centers; need for longitudinal validation of blood-based surrogates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e9991.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau pathology</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurofibrillary tangles / tau protein pathology</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intracellular aggregation of hyperphosphorylated tau forming neurofibrillary tangles associated with neuronal dysfunction and clinical decline in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular (protein aggregation / cytoskeletal dysfunction)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Abnormal tau phosphorylation and aggregation into neurofibrillary tangles; measured via CSF phosphorylated tau (p-tau), total tau (t-tau), and tau PET tracers (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240) that bind tau aggregates in vivo.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review cites that increased CSF t-tau and p-tau correlate with AD pathology; tau PET imaging can localize and quantify tau pathology and correlates with disease course and severity; plasma p-tau181 levels increase with clinical severity and associate with both tau and amyloid PET in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No primary refuting experimental data presented in this review, but the paper notes the need for further validation of tau PET tracers and for standardization; some limits implied by tracer specificity and evolving evidence base.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>molecular imaging and fluid biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Tau PET imaging using selective radiotracers (18F-AV-1451/flortaucipir, 18F-MK-6240) to detect aggregated tau; CSF p-tau and plasma phospho-tau (e.g., p-tau181) assays to quantify tau-related pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Review states tau PET is an 'emerging application' showing promise for identifying tau pathology; plasma p-tau biomarkers have been shown in cited studies to increase with clinical severity and correlate with PET. Table-level summary groups tau assays within CSF and blood-based biomarker categories (CSF biomarkers sensitivity ~85–90%, specificity ~90–95%; blood-based markers sensitivity ~70–80%, specificity ~80–90%). Stage: tau markers correlate with disease severity and can be useful in prodromal/early symptomatic stages and for staging progression.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review (citing imaging and biomarker studies, cohort and phase 2 imaging trials)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Participants across cited studies include individuals with MCI, AD dementia, and cognitively normal older adults with PET and fluid biomarker sampling; this review synthesizes those findings.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Tau PET tracer specificity and off-target binding remain concerns; need for standardization and longitudinal validation; blood-based tau assays are promising but require broader validation across populations and harmonization of assays.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e9991.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOE4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Apolipoprotein E epsilon-4 allele (APOE4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A genetic risk factor allele (APOE ε4) strongly associated with increased risk and earlier onset of late‑onset AD, implicated in amyloid and network-level changes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic risk factor</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Presence of the APOE ε4 allele increases risk for AD and has been associated with alterations in brain functional connectivity, even in the absence of amyloid deposition in some cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review cites work showing APOE4 disrupts resting-state fMRI connectivity without amyloid plaques or decreased CSF Aβ42, supporting an early network vulnerability linked to APOE4 status; numerous referenced studies establish APOE4 as a risk allele for AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct refuting studies given in the review; implicit limitation that APOE4 is a risk factor not a deterministic cause and many carriers remain cognitively normal.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>genetic screening / imaging correlation</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Genotyping for APOE alleles (blood or saliva DNA assays); correlated imaging findings (e.g., resting-state fMRI connectivity disruptions) have been reported in APOE4 carriers.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Genetic testing reliably identifies APOE genotype (high analytic sensitivity/specificity for allele detection). As a predictive marker for clinical conversion, APOE4 confers increased risk but is neither fully sensitive nor specific for individual prognosis; the review does not provide explicit numeric sensitivity/specificity for APOE4 as a diagnostic predictor.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing observational neuroimaging/genetic association studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited studies include cognitively normal older adults and clinical cohorts stratified by APOE genotype; sizes vary across cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>APOE4 increases risk but is neither necessary nor sufficient for AD; presence of imaging changes in APOE4 carriers without amyloid complicates interpretation; ethical and counseling considerations for genetic risk disclosure; population and ancestry differences may affect risk estimates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e9991.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular contributions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular abnormalities / cerebrovascular contributions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Vascular dysfunction, reduced perfusion, or small-vessel disease contributing to cognitive decline and interacting with AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>vascular</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Cerebrovascular abnormalities (reduced regional blood flow, ischemia, small vessel disease) can contribute to cognitive impairment and may interact with classical AD pathologies; vascular-related biomarkers are being studied in CSF and imaging modalities (SPECT, MRI).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review notes SPECT can show regional hypoperfusion and aid differential diagnosis; CSF vascular markers are under study and vascular abnormalities are listed among candidate biomarkers investigated for early diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Review does not provide strong counter-evidence but indicates vascular markers are still under active investigation and not as established as amyloid/tau biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>neuroimaging and fluid biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>SPECT imaging for regional perfusion abnormalities; MRI for structural vascular lesions/white matter changes; investigational CSF markers of vascular dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>SPECT and MRI have diagnostic utility for detecting perfusion or structural vascular changes and may assist in differential diagnosis; table groups brain imaging generally (PET, MRI) with MRI sensitivity ~85% (specificity varied) and SPECT discussed qualitatively. Stage: useful for symptomatic and differential diagnosis; may detect vascular contributions earlier than advanced neurodegeneration in some cases.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing imaging and biomarker studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited studies include clinical populations undergoing SPECT/MRI as part of differential dementia assessment; not quantified in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Vascular contributions are heterogeneous and comorbid with AD pathologies, making causal attribution hard; vascular biomarkers are less standardized; imaging-based vascular assessments may lack specificity for AD vs other vascular cognitive impairments.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e9991.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Synaptic dysfunction & neuroinflammation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Synaptic dysfunction and neuroinflammatory processes</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Early synaptic loss/dysfunction and neuroinflammatory responses (microglial/astrocytic activation) proposed as drivers or amplifiers of AD pathology and cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular / cellular (synaptic & immune)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Markers of synaptic dysfunction and neuroinflammation (candidate CSF and blood biomarkers) are under investigation as contributors to AD pathophysiology and as early indicators of disease progression.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review identifies synaptic dysfunction and neuroinflammatory markers among novel biomarkers being studied (e.g., neurogranin in CSF as synaptic marker is cited in references); such markers have been associated with AD pathology in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Evidence is emerging; the review emphasizes ongoing research and the need for additional validation rather than definitive refutation.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>fluid biomarkers (CSF, blood), potentially imaging of inflammation</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CSF markers (e.g., neurogranin) and emerging blood assays aim to quantify synaptic proteins and inflammatory mediators; PET tracers for neuroinflammation exist but are not detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not reported numerically in the review for most synaptic/inflammatory markers; the review groups CSF biomarkers overall as having sensitivities ~85–90% and specificities ~90–95% when combined (Aβ, t-tau, p-tau), but individual synaptic/inflammatory markers require further validation. Stage: promising for early and prodromal detection, but still investigational.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review of biomarker discovery and cohort studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Varied cohorts in cited studies; early-stage and preclinical individuals included in some biomarker investigations.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Markers are still exploratory; lack of standardization and limited longitudinal validation; potential overlap with other neurodegenerative or inflammatory conditions reduces specificity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e9991.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Mitochondrial/lysosomal dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mitochondrial and lysosomal pathway alterations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Alterations in mitochondrial gene expression and lysosomal protein dysregulation have been reported early in AD and are proposed as contributing mechanisms to neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular / cellular (metabolic / proteostasis)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Studies cited report changes in mitochondrial genes in blood and altered lysosomal proteins in neural-derived plasma exosomes in preclinical AD, implicating energy metabolism and protein degradation pathways in disease development.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The review cites specific studies showing early mitochondrial gene expression changes in blood and altered lysosomal proteins in exosomes from preclinical AD participants, suggesting peripheral signatures of these processes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>These findings are preliminary and require replication; the review points out the need for further validation and larger longitudinal cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>blood-based genomic/transcriptomic assays; exosome proteomics</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Blood assays for altered mitochondrial gene expression; isolation and proteomic analysis of neural-derived exosomes from plasma to detect lysosomal protein changes.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Review describes these as promising early signals but does not provide consolidated sensitivity/specificity metrics; categorized under emerging blood-based/liquid biopsy approaches (table: blood-based markers sensitivity ~70–80%, specificity ~80–90% as a broad estimate for blood biomarkers). Stage: reported in preclinical stages in cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing discovery and cohort biomarker studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited studies included individuals in preclinical or early stages of AD and control groups; specific sample sizes vary by study and are not enumerated in this review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Techniques are experimental; isolation methods for exosomes and gene-expression assays vary across labs, requiring standardization; clinical utility not yet established.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e9991.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neurofilament light (NfL)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurofilament light chain (NfL) as a neurodegeneration marker</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An axonal structural protein released into CSF and blood during neuroaxonal damage; elevated NfL reflects neurodegeneration and predicts progression but is not AD-specific.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular marker of neurodegeneration (not a primary causal mechanism)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>NfL is released with neuronal injury/degeneration; elevated CSF or blood NfL correlates with neurodegeneration and clinical progression in AD and presymptomatic individuals.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review cites studies showing serum/plasma NfL dynamics predict neurodegeneration and clinical progression in presymptomatic AD and that longitudinal plasma NfL associates with neurodegeneration in patients with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>NfL is a general marker of axonal injury and not specific to AD pathology; elevated levels occur across multiple neurodegenerative and neurological conditions, limiting specificity as a diagnostic cause marker.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>fluid biomarker (blood, CSF)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Measurement of NfL concentration in plasma/serum or CSF using sensitive immunoassays (e.g., Simoa-type platforms).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The review highlights predictive value for neurodegeneration and progression in cited longitudinal studies but does not present single-number sensitivity/specificity for NfL alone; blood-based biomarker category in table gives a broad sensitivity ~70–80% and specificity ~80–90% for blood biomarkers collectively. Stage: useful for presymptomatic and early-stage monitoring of neurodegeneration and treatment response.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing longitudinal cohort biomarker studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited cohorts include presymptomatic mutation carriers, patients with AD, and longitudinal observational samples; sizes vary across individual cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>High sensitivity to neurodegeneration but low disease specificity; elevation in other neurological disorders reduces diagnostic specificity; clinical cutpoints and standardization across assay platforms remain issues.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e9991.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cognitive testing</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Clinical cognitive assessments (MMSE, MoCA, ADAS-Cog, CDR, AD8)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Standardized neuropsychological screening and assessment instruments that quantify cognitive domains to detect impairment and stage dementia clinically.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>diagnostic tool (clinical assessment)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Cognitive tests themselves are not causes but are primary clinical tools for detecting symptomatic cognitive impairment across domains (memory, executive function, language, visuospatial).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Widely used, validated instruments (MMSE, MoCA, ADAS-Cog, CDR, informant tools like AD8) provide objective scores correlated with cognitive status and dementia severity; used across trials and clinics as outcome/diagnostic measures.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not a causal entity; limitations include subjectivity, ceiling effects in early disease, cultural/educational biases, and lower sensitivity for very early (preclinical) stages.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>clinical cognitive test / screening</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Structured neuropsychological batteries and brief screeners (MMSE, MoCA) administered by clinicians to assess multiple cognitive domains and assign severity/staging (e.g., CDR).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Table summary: cognitive assessment sensitivity ~60–85%, specificity ~70–85% (range depending on instrument and cutoff). Stage: more sensitive for symptomatic (MCI to dementia) stages; less sensitive for preclinical pathology without overt cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review (citing validation and normative studies)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Populations in cited work include community-dwelling older adults, clinical memory clinic samples, and research cohorts; performance varies by age, education and clinical context.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Subjectivity and inter-rater variability; cultural, language, and education biases affecting scores; poor sensitivity for preclinical AD; time and specialist resource requirements for comprehensive neuropsychological testing.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e9991.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroimaging (MRI/PET/SPECT/fMRI)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroimaging modalities (structural MRI, amyloid/tau PET, SPECT, fMRI)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural, molecular, and functional brain imaging methods that detect atrophy, molecular pathology (amyloid, tau), perfusion/metabolism changes, and functional network alterations in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>diagnostic modality (imaging biomarker)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Imaging reveals structural atrophy (MRI medial temporal lobe), fibrillar amyloid and tau deposition (amyloid and tau PET), regional perfusion/metabolism deficits (SPECT), and network functional connectivity changes (fMRI) associated with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>MRI shows characteristic atrophy; amyloid PET visualizes amyloid plaque burden and distinguishes AD from other dementias in many studies; tau PET identifies tau aggregates and correlates with severity; fMRI reveals default mode network and connectivity disruptions; SPECT shows hypoperfusion patterns aiding differential diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Imaging findings can be non-specific (e.g., atrophy in other disorders), amyloid PET positivity in cognitively normal individuals complicates interpretation; cost, radiation (PET), and variable availability limit broad application.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>neuroimaging</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Structural MRI for atrophy and exclusion of other pathology; amyloid PET (PiB and 18F tracers) for Aβ; tau PET for tau tangles; SPECT for perfusion; fMRI for functional network analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Table (authors' summary): PET (amyloid) sensitivity ~70–90%, specificity ~90–95%; MRI sensitivity ~85% (specificity variable); fMRI and SPECT described qualitatively as useful for functional and perfusion abnormalities. Stage: PET and advanced imaging can detect molecular pathology in preclinical/prodromal stages; MRI often shows changes later but can detect medial temporal atrophy early in symptomatic stages.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing imaging trials, cohort and meta-analytic studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited imaging studies include cognitively normal older adults, MCI, AD dementia cohorts, and clinic populations; exact sizes vary among cited reports.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>High cost and limited availability (especially PET); exposure to radioactive tracers for PET; variability in analytic pipelines and thresholds; amyloid PET positivity in non-demented individuals undermines simple causal inference; need for standardization and harmonization across centers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e9991.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blood-based biomarkers / liquid biopsy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Blood-based biomarkers and liquid biopsies (plasma Aβ, plasma p-tau, NfL, exosomes, cfDNA/RNA)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive assays measuring AD-related proteins or nucleic acids in blood or other bodily fluids to detect or monitor AD pathology and progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>diagnostic biomarker (fluid)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Assays measure plasma Aβ peptides (Aβ42, Aβ40 and ratios), plasma phosphorylated tau (p-tau181 and others), neurofilament light (NfL), neural-derived exosomal proteins, and cell-free nucleic acids as proxies for central AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review cites high-performance plasma Aβ studies (e.g., Nakamura et al.) and plasma p-tau studies showing correlation with PET and clinical severity; NfL dynamics predict neurodegeneration and progression in presymptomatic cohorts; exosomal lysosomal protein alterations reported in preclinical AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Blood biomarkers are variable across platforms and assays; many are still under validation and lack broad standardization; peripheral signals may be influenced by non-CNS factors and comorbidities.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>blood-based fluid biomarker / liquid biopsy</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>High-sensitivity immunoassays or mass-spectrometry-based assays on plasma/serum to quantify Aβ species, p-tau isoforms, NfL; isolation of neural-derived exosomes from plasma for proteomic analysis; cfDNA/RNA profiling.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Table summary (aggregate for blood-based markers): sensitivity ~70–80%, specificity ~80–90% as an emerging category; individual high-performance reports cited (e.g., some plasma Aβ methods reported high discrimination in individual studies). Stage: promising for early/preclinical detection and for scalable population screening, but performance varies by assay and requires validation.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review synthesizing discovery, validation, and cohort studies (including phase studies cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited studies include preclinical cohorts, MCI, AD dementia, and community samples across multiple publications; numbers and demographics vary by study.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Need for assay harmonization, reproducibility across labs, and validation in diverse populations; potential variability due to comorbidities, peripheral metabolism, and pre-analytic factors; regulatory and reimbursement pathways still evolving.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9991.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e9991.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Machine learning on imaging/biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Machine-learning algorithms applied to neuroimaging and multimodal biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Application of supervised and unsupervised machine-learning methods to imaging and biomarker datasets to improve early detection, classification, and prognostic prediction in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>analytic method (algorithmic detection)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Machine learning (support vector machines, random forests, deep learning, graph-based methods, transfer learning) is used to detect complex patterns in structural/functional imaging, combine multimodal biomarkers, and classify AD vs controls or predict progression.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Review cites examples where machine-learning applied to fMRI or multimodal imaging can detect early functional connectivity abnormalities and improve discrimination; systematic reviews of ML classification (random forest, etc.) are referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not a causal claim; methodological limitations exist—overfitting, lack of generalizability, variable performance across datasets, and interpretability issues.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>algorithmic / computational diagnostic approach</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Algorithms trained on neuroimaging and biomarker data to classify disease status, identify early functional connectivity changes, or predict cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Table summary (aggregate): machine learning methods sensitivity ~80–90% and specificity ~85–90% in cited studies/reviews—performance depends on input data quality, task, and cross-validation methods. Stage: applied to detect early functional/structural changes and to aid early/prodromal detection when combined with biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing algorithm development studies, systematic reviews of ML in imaging</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Datasets include research cohorts with imaging and biomarker data (e.g., ADNI and similar cohorts) used for algorithm training and testing; heterogeneity across studies.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Challenges include data quality, small sample sizes, lack of external validation, interpretability of models, biases in training data, and need for standardization for clinical deployment.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations", 'publication_date_yy_mm': '2023-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to <em>(Rating: 2)</em></li>
                <li>High performance plasma amyloid-β biomarkers for Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography <em>(Rating: 2)</em></li>
                <li>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease <em>(Rating: 2)</em></li>
                <li>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis <em>(Rating: 2)</em></li>
                <li>Imaging beta-amyloid burden in aging and dementia <em>(Rating: 2)</em></li>
                <li>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease <em>(Rating: 2)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-9991",
    "paper_id": "paper-261673400",
    "extraction_schema_id": "extraction-schema-170",
    "extracted_data": [
        {
            "name_short": "Aβ accumulation",
            "name_full": "Amyloid-beta (Aβ) accumulation / plaques",
            "brief_description": "Extracellular accumulation of amyloid-beta peptides (notably Aβ42) forming plaques in the brain, long considered a central pathological hallmark and proposed upstream cause of Alzheimer's disease (AD).",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "molecular (protein aggregation)",
            "cause_description": "Aggregation and deposition of amyloid-beta peptides (Aβ42, Aβ40) into extracellular plaques in brain tissue; implicated by pathological studies and targeted by amyloid PET tracers and CSF/plasma Aβ assays.",
            "evidence_for_cause": "Reviewed literature and longstanding neuropathology link Aβ plaques with AD; decreased CSF Aβ42 and increased brain amyloid on amyloid PET are repeatedly associated with AD and prodromal stages; amyloid PET tracers (PiB, florbetapir, florbetaben, flutemetamol) reliably visualize cortical amyloid burden; CSF Aβ42 and Aβ42/Aβ40 ratios are diagnostic in many cited studies.",
            "evidence_against_cause": "The review notes that amyloid deposition can be present in persons without dementia (cites meta-analyses) and cites discussions of 'progress and problems' with the amyloid hypothesis, implying that amyloid presence does not always equate to clinical disease and that clinical trials targeting amyloid have had mixed/negative results.",
            "detection_method_type": "biomarker / molecular imaging",
            "detection_method_description": "Amyloid PET imaging (PiB, florbetapir, florbetaben, flutemetamol) visualizes fibrillar Aβ deposits; CSF Aβ42 (and Aβ42/Aβ40 ratios) measure soluble amyloid-related peptides; plasma Aβ assays (Aβ42, Aβ40 ratios) and high-performance plasma Aβ tests are emerging as blood-based surrogates.",
            "detection_performance": "Amyloid PET (table summary): sensitivity ~70–90%, specificity ~90–95% for detecting amyloid deposition; CSF Aβ42 (with t-tau/p-tau) reported combined CSF biomarker sensitivity ~85–90% and specificity ~90–95% for AD vs controls in review; blood-based Aβ assays reported promising performance but lower ranges in the table (blood-based markers sensitivity ~70–80%, specificity ~80–90%). Stage: effective at preclinical and prodromal (early) stages for detecting pathology prior to prominent clinical symptoms.",
            "study_type": "review of molecular, imaging and clinical studies (systematic search yielding 59 studies)",
            "study_population": "Varied cohorts and study types across cited literature (as summarized in review); includes asymptomatic older adults, MCI, AD dementia cohorts, and population/meta-analytic studies; this review did not run primary experiments.",
            "controversies_or_limitations": "Presence of amyloid in cognitively normal individuals (prevalence in non-demented populations) complicates causal inference; the amyloid hypothesis has recognized 'progress and problems' and therapeutic trials targeting amyloid have produced mixed results; PET and some CSF assays are costly or invasive (lumbar puncture); lack of harmonized thresholds and standardization across centers; need for longitudinal validation of blood-based surrogates.",
            "uuid": "e9991.0",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Tau pathology",
            "name_full": "Neurofibrillary tangles / tau protein pathology",
            "brief_description": "Intracellular aggregation of hyperphosphorylated tau forming neurofibrillary tangles associated with neuronal dysfunction and clinical decline in AD.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "molecular (protein aggregation / cytoskeletal dysfunction)",
            "cause_description": "Abnormal tau phosphorylation and aggregation into neurofibrillary tangles; measured via CSF phosphorylated tau (p-tau), total tau (t-tau), and tau PET tracers (e.g., 18F-AV-1451/flortaucipir, 18F-MK-6240) that bind tau aggregates in vivo.",
            "evidence_for_cause": "Review cites that increased CSF t-tau and p-tau correlate with AD pathology; tau PET imaging can localize and quantify tau pathology and correlates with disease course and severity; plasma p-tau181 levels increase with clinical severity and associate with both tau and amyloid PET in cited literature.",
            "evidence_against_cause": "No primary refuting experimental data presented in this review, but the paper notes the need for further validation of tau PET tracers and for standardization; some limits implied by tracer specificity and evolving evidence base.",
            "detection_method_type": "molecular imaging and fluid biomarker",
            "detection_method_description": "Tau PET imaging using selective radiotracers (18F-AV-1451/flortaucipir, 18F-MK-6240) to detect aggregated tau; CSF p-tau and plasma phospho-tau (e.g., p-tau181) assays to quantify tau-related pathology.",
            "detection_performance": "Review states tau PET is an 'emerging application' showing promise for identifying tau pathology; plasma p-tau biomarkers have been shown in cited studies to increase with clinical severity and correlate with PET. Table-level summary groups tau assays within CSF and blood-based biomarker categories (CSF biomarkers sensitivity ~85–90%, specificity ~90–95%; blood-based markers sensitivity ~70–80%, specificity ~80–90%). Stage: tau markers correlate with disease severity and can be useful in prodromal/early symptomatic stages and for staging progression.",
            "study_type": "review (citing imaging and biomarker studies, cohort and phase 2 imaging trials)",
            "study_population": "Participants across cited studies include individuals with MCI, AD dementia, and cognitively normal older adults with PET and fluid biomarker sampling; this review synthesizes those findings.",
            "controversies_or_limitations": "Tau PET tracer specificity and off-target binding remain concerns; need for standardization and longitudinal validation; blood-based tau assays are promising but require broader validation across populations and harmonization of assays.",
            "uuid": "e9991.1",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "APOE4",
            "name_full": "Apolipoprotein E epsilon-4 allele (APOE4)",
            "brief_description": "A genetic risk factor allele (APOE ε4) strongly associated with increased risk and earlier onset of late‑onset AD, implicated in amyloid and network-level changes.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "genetic risk factor",
            "cause_description": "Presence of the APOE ε4 allele increases risk for AD and has been associated with alterations in brain functional connectivity, even in the absence of amyloid deposition in some cited studies.",
            "evidence_for_cause": "Review cites work showing APOE4 disrupts resting-state fMRI connectivity without amyloid plaques or decreased CSF Aβ42, supporting an early network vulnerability linked to APOE4 status; numerous referenced studies establish APOE4 as a risk allele for AD.",
            "evidence_against_cause": "No direct refuting studies given in the review; implicit limitation that APOE4 is a risk factor not a deterministic cause and many carriers remain cognitively normal.",
            "detection_method_type": "genetic screening / imaging correlation",
            "detection_method_description": "Genotyping for APOE alleles (blood or saliva DNA assays); correlated imaging findings (e.g., resting-state fMRI connectivity disruptions) have been reported in APOE4 carriers.",
            "detection_performance": "Genetic testing reliably identifies APOE genotype (high analytic sensitivity/specificity for allele detection). As a predictive marker for clinical conversion, APOE4 confers increased risk but is neither fully sensitive nor specific for individual prognosis; the review does not provide explicit numeric sensitivity/specificity for APOE4 as a diagnostic predictor.",
            "study_type": "review citing observational neuroimaging/genetic association studies",
            "study_population": "Cited studies include cognitively normal older adults and clinical cohorts stratified by APOE genotype; sizes vary across cited literature.",
            "controversies_or_limitations": "APOE4 increases risk but is neither necessary nor sufficient for AD; presence of imaging changes in APOE4 carriers without amyloid complicates interpretation; ethical and counseling considerations for genetic risk disclosure; population and ancestry differences may affect risk estimates.",
            "uuid": "e9991.2",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Vascular contributions",
            "name_full": "Vascular abnormalities / cerebrovascular contributions",
            "brief_description": "Vascular dysfunction, reduced perfusion, or small-vessel disease contributing to cognitive decline and interacting with AD pathology.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "vascular",
            "cause_description": "Cerebrovascular abnormalities (reduced regional blood flow, ischemia, small vessel disease) can contribute to cognitive impairment and may interact with classical AD pathologies; vascular-related biomarkers are being studied in CSF and imaging modalities (SPECT, MRI).",
            "evidence_for_cause": "Review notes SPECT can show regional hypoperfusion and aid differential diagnosis; CSF vascular markers are under study and vascular abnormalities are listed among candidate biomarkers investigated for early diagnosis.",
            "evidence_against_cause": "Review does not provide strong counter-evidence but indicates vascular markers are still under active investigation and not as established as amyloid/tau biomarkers.",
            "detection_method_type": "neuroimaging and fluid biomarker",
            "detection_method_description": "SPECT imaging for regional perfusion abnormalities; MRI for structural vascular lesions/white matter changes; investigational CSF markers of vascular dysfunction.",
            "detection_performance": "SPECT and MRI have diagnostic utility for detecting perfusion or structural vascular changes and may assist in differential diagnosis; table groups brain imaging generally (PET, MRI) with MRI sensitivity ~85% (specificity varied) and SPECT discussed qualitatively. Stage: useful for symptomatic and differential diagnosis; may detect vascular contributions earlier than advanced neurodegeneration in some cases.",
            "study_type": "review citing imaging and biomarker studies",
            "study_population": "Cited studies include clinical populations undergoing SPECT/MRI as part of differential dementia assessment; not quantified in this review.",
            "controversies_or_limitations": "Vascular contributions are heterogeneous and comorbid with AD pathologies, making causal attribution hard; vascular biomarkers are less standardized; imaging-based vascular assessments may lack specificity for AD vs other vascular cognitive impairments.",
            "uuid": "e9991.3",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Synaptic dysfunction & neuroinflammation",
            "name_full": "Synaptic dysfunction and neuroinflammatory processes",
            "brief_description": "Early synaptic loss/dysfunction and neuroinflammatory responses (microglial/astrocytic activation) proposed as drivers or amplifiers of AD pathology and cognitive decline.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "molecular / cellular (synaptic & immune)",
            "cause_description": "Markers of synaptic dysfunction and neuroinflammation (candidate CSF and blood biomarkers) are under investigation as contributors to AD pathophysiology and as early indicators of disease progression.",
            "evidence_for_cause": "Review identifies synaptic dysfunction and neuroinflammatory markers among novel biomarkers being studied (e.g., neurogranin in CSF as synaptic marker is cited in references); such markers have been associated with AD pathology in cited literature.",
            "evidence_against_cause": "Evidence is emerging; the review emphasizes ongoing research and the need for additional validation rather than definitive refutation.",
            "detection_method_type": "fluid biomarkers (CSF, blood), potentially imaging of inflammation",
            "detection_method_description": "CSF markers (e.g., neurogranin) and emerging blood assays aim to quantify synaptic proteins and inflammatory mediators; PET tracers for neuroinflammation exist but are not detailed in this review.",
            "detection_performance": "Not reported numerically in the review for most synaptic/inflammatory markers; the review groups CSF biomarkers overall as having sensitivities ~85–90% and specificities ~90–95% when combined (Aβ, t-tau, p-tau), but individual synaptic/inflammatory markers require further validation. Stage: promising for early and prodromal detection, but still investigational.",
            "study_type": "review of biomarker discovery and cohort studies",
            "study_population": "Varied cohorts in cited studies; early-stage and preclinical individuals included in some biomarker investigations.",
            "controversies_or_limitations": "Markers are still exploratory; lack of standardization and limited longitudinal validation; potential overlap with other neurodegenerative or inflammatory conditions reduces specificity.",
            "uuid": "e9991.4",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Mitochondrial/lysosomal dysfunction",
            "name_full": "Mitochondrial and lysosomal pathway alterations",
            "brief_description": "Alterations in mitochondrial gene expression and lysosomal protein dysregulation have been reported early in AD and are proposed as contributing mechanisms to neurodegeneration.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "molecular / cellular (metabolic / proteostasis)",
            "cause_description": "Studies cited report changes in mitochondrial genes in blood and altered lysosomal proteins in neural-derived plasma exosomes in preclinical AD, implicating energy metabolism and protein degradation pathways in disease development.",
            "evidence_for_cause": "The review cites specific studies showing early mitochondrial gene expression changes in blood and altered lysosomal proteins in exosomes from preclinical AD participants, suggesting peripheral signatures of these processes.",
            "evidence_against_cause": "These findings are preliminary and require replication; the review points out the need for further validation and larger longitudinal cohorts.",
            "detection_method_type": "blood-based genomic/transcriptomic assays; exosome proteomics",
            "detection_method_description": "Blood assays for altered mitochondrial gene expression; isolation and proteomic analysis of neural-derived exosomes from plasma to detect lysosomal protein changes.",
            "detection_performance": "Review describes these as promising early signals but does not provide consolidated sensitivity/specificity metrics; categorized under emerging blood-based/liquid biopsy approaches (table: blood-based markers sensitivity ~70–80%, specificity ~80–90% as a broad estimate for blood biomarkers). Stage: reported in preclinical stages in cited studies.",
            "study_type": "review citing discovery and cohort biomarker studies",
            "study_population": "Cited studies included individuals in preclinical or early stages of AD and control groups; specific sample sizes vary by study and are not enumerated in this review summary.",
            "controversies_or_limitations": "Techniques are experimental; isolation methods for exosomes and gene-expression assays vary across labs, requiring standardization; clinical utility not yet established.",
            "uuid": "e9991.5",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Neurofilament light (NfL)",
            "name_full": "Neurofilament light chain (NfL) as a neurodegeneration marker",
            "brief_description": "An axonal structural protein released into CSF and blood during neuroaxonal damage; elevated NfL reflects neurodegeneration and predicts progression but is not AD-specific.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "molecular marker of neurodegeneration (not a primary causal mechanism)",
            "cause_description": "NfL is released with neuronal injury/degeneration; elevated CSF or blood NfL correlates with neurodegeneration and clinical progression in AD and presymptomatic individuals.",
            "evidence_for_cause": "Review cites studies showing serum/plasma NfL dynamics predict neurodegeneration and clinical progression in presymptomatic AD and that longitudinal plasma NfL associates with neurodegeneration in patients with AD.",
            "evidence_against_cause": "NfL is a general marker of axonal injury and not specific to AD pathology; elevated levels occur across multiple neurodegenerative and neurological conditions, limiting specificity as a diagnostic cause marker.",
            "detection_method_type": "fluid biomarker (blood, CSF)",
            "detection_method_description": "Measurement of NfL concentration in plasma/serum or CSF using sensitive immunoassays (e.g., Simoa-type platforms).",
            "detection_performance": "The review highlights predictive value for neurodegeneration and progression in cited longitudinal studies but does not present single-number sensitivity/specificity for NfL alone; blood-based biomarker category in table gives a broad sensitivity ~70–80% and specificity ~80–90% for blood biomarkers collectively. Stage: useful for presymptomatic and early-stage monitoring of neurodegeneration and treatment response.",
            "study_type": "review citing longitudinal cohort biomarker studies",
            "study_population": "Cited cohorts include presymptomatic mutation carriers, patients with AD, and longitudinal observational samples; sizes vary across individual cited studies.",
            "controversies_or_limitations": "High sensitivity to neurodegeneration but low disease specificity; elevation in other neurological disorders reduces diagnostic specificity; clinical cutpoints and standardization across assay platforms remain issues.",
            "uuid": "e9991.6",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Cognitive testing",
            "name_full": "Clinical cognitive assessments (MMSE, MoCA, ADAS-Cog, CDR, AD8)",
            "brief_description": "Standardized neuropsychological screening and assessment instruments that quantify cognitive domains to detect impairment and stage dementia clinically.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "diagnostic tool (clinical assessment)",
            "cause_description": "Cognitive tests themselves are not causes but are primary clinical tools for detecting symptomatic cognitive impairment across domains (memory, executive function, language, visuospatial).",
            "evidence_for_cause": "Widely used, validated instruments (MMSE, MoCA, ADAS-Cog, CDR, informant tools like AD8) provide objective scores correlated with cognitive status and dementia severity; used across trials and clinics as outcome/diagnostic measures.",
            "evidence_against_cause": "Not a causal entity; limitations include subjectivity, ceiling effects in early disease, cultural/educational biases, and lower sensitivity for very early (preclinical) stages.",
            "detection_method_type": "clinical cognitive test / screening",
            "detection_method_description": "Structured neuropsychological batteries and brief screeners (MMSE, MoCA) administered by clinicians to assess multiple cognitive domains and assign severity/staging (e.g., CDR).",
            "detection_performance": "Table summary: cognitive assessment sensitivity ~60–85%, specificity ~70–85% (range depending on instrument and cutoff). Stage: more sensitive for symptomatic (MCI to dementia) stages; less sensitive for preclinical pathology without overt cognitive impairment.",
            "study_type": "review (citing validation and normative studies)",
            "study_population": "Populations in cited work include community-dwelling older adults, clinical memory clinic samples, and research cohorts; performance varies by age, education and clinical context.",
            "controversies_or_limitations": "Subjectivity and inter-rater variability; cultural, language, and education biases affecting scores; poor sensitivity for preclinical AD; time and specialist resource requirements for comprehensive neuropsychological testing.",
            "uuid": "e9991.7",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Neuroimaging (MRI/PET/SPECT/fMRI)",
            "name_full": "Neuroimaging modalities (structural MRI, amyloid/tau PET, SPECT, fMRI)",
            "brief_description": "Structural, molecular, and functional brain imaging methods that detect atrophy, molecular pathology (amyloid, tau), perfusion/metabolism changes, and functional network alterations in AD.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "diagnostic modality (imaging biomarker)",
            "cause_description": "Imaging reveals structural atrophy (MRI medial temporal lobe), fibrillar amyloid and tau deposition (amyloid and tau PET), regional perfusion/metabolism deficits (SPECT), and network functional connectivity changes (fMRI) associated with AD.",
            "evidence_for_cause": "MRI shows characteristic atrophy; amyloid PET visualizes amyloid plaque burden and distinguishes AD from other dementias in many studies; tau PET identifies tau aggregates and correlates with severity; fMRI reveals default mode network and connectivity disruptions; SPECT shows hypoperfusion patterns aiding differential diagnosis.",
            "evidence_against_cause": "Imaging findings can be non-specific (e.g., atrophy in other disorders), amyloid PET positivity in cognitively normal individuals complicates interpretation; cost, radiation (PET), and variable availability limit broad application.",
            "detection_method_type": "neuroimaging",
            "detection_method_description": "Structural MRI for atrophy and exclusion of other pathology; amyloid PET (PiB and 18F tracers) for Aβ; tau PET for tau tangles; SPECT for perfusion; fMRI for functional network analysis.",
            "detection_performance": "Table (authors' summary): PET (amyloid) sensitivity ~70–90%, specificity ~90–95%; MRI sensitivity ~85% (specificity variable); fMRI and SPECT described qualitatively as useful for functional and perfusion abnormalities. Stage: PET and advanced imaging can detect molecular pathology in preclinical/prodromal stages; MRI often shows changes later but can detect medial temporal atrophy early in symptomatic stages.",
            "study_type": "review citing imaging trials, cohort and meta-analytic studies",
            "study_population": "Cited imaging studies include cognitively normal older adults, MCI, AD dementia cohorts, and clinic populations; exact sizes vary among cited reports.",
            "controversies_or_limitations": "High cost and limited availability (especially PET); exposure to radioactive tracers for PET; variability in analytic pipelines and thresholds; amyloid PET positivity in non-demented individuals undermines simple causal inference; need for standardization and harmonization across centers.",
            "uuid": "e9991.8",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Blood-based biomarkers / liquid biopsy",
            "name_full": "Blood-based biomarkers and liquid biopsies (plasma Aβ, plasma p-tau, NfL, exosomes, cfDNA/RNA)",
            "brief_description": "Non-invasive assays measuring AD-related proteins or nucleic acids in blood or other bodily fluids to detect or monitor AD pathology and progression.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "diagnostic biomarker (fluid)",
            "cause_description": "Assays measure plasma Aβ peptides (Aβ42, Aβ40 and ratios), plasma phosphorylated tau (p-tau181 and others), neurofilament light (NfL), neural-derived exosomal proteins, and cell-free nucleic acids as proxies for central AD pathology.",
            "evidence_for_cause": "Review cites high-performance plasma Aβ studies (e.g., Nakamura et al.) and plasma p-tau studies showing correlation with PET and clinical severity; NfL dynamics predict neurodegeneration and progression in presymptomatic cohorts; exosomal lysosomal protein alterations reported in preclinical AD.",
            "evidence_against_cause": "Blood biomarkers are variable across platforms and assays; many are still under validation and lack broad standardization; peripheral signals may be influenced by non-CNS factors and comorbidities.",
            "detection_method_type": "blood-based fluid biomarker / liquid biopsy",
            "detection_method_description": "High-sensitivity immunoassays or mass-spectrometry-based assays on plasma/serum to quantify Aβ species, p-tau isoforms, NfL; isolation of neural-derived exosomes from plasma for proteomic analysis; cfDNA/RNA profiling.",
            "detection_performance": "Table summary (aggregate for blood-based markers): sensitivity ~70–80%, specificity ~80–90% as an emerging category; individual high-performance reports cited (e.g., some plasma Aβ methods reported high discrimination in individual studies). Stage: promising for early/preclinical detection and for scalable population screening, but performance varies by assay and requires validation.",
            "study_type": "review synthesizing discovery, validation, and cohort studies (including phase studies cited)",
            "study_population": "Cited studies include preclinical cohorts, MCI, AD dementia, and community samples across multiple publications; numbers and demographics vary by study.",
            "controversies_or_limitations": "Need for assay harmonization, reproducibility across labs, and validation in diverse populations; potential variability due to comorbidities, peripheral metabolism, and pre-analytic factors; regulatory and reimbursement pathways still evolving.",
            "uuid": "e9991.9",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        },
        {
            "name_short": "Machine learning on imaging/biomarkers",
            "name_full": "Machine-learning algorithms applied to neuroimaging and multimodal biomarkers",
            "brief_description": "Application of supervised and unsupervised machine-learning methods to imaging and biomarker datasets to improve early detection, classification, and prognostic prediction in AD.",
            "citation_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
            "mention_or_use": "mention",
            "cause_type": "analytic method (algorithmic detection)",
            "cause_description": "Machine learning (support vector machines, random forests, deep learning, graph-based methods, transfer learning) is used to detect complex patterns in structural/functional imaging, combine multimodal biomarkers, and classify AD vs controls or predict progression.",
            "evidence_for_cause": "Review cites examples where machine-learning applied to fMRI or multimodal imaging can detect early functional connectivity abnormalities and improve discrimination; systematic reviews of ML classification (random forest, etc.) are referenced.",
            "evidence_against_cause": "Not a causal claim; methodological limitations exist—overfitting, lack of generalizability, variable performance across datasets, and interpretability issues.",
            "detection_method_type": "algorithmic / computational diagnostic approach",
            "detection_method_description": "Algorithms trained on neuroimaging and biomarker data to classify disease status, identify early functional connectivity changes, or predict cognitive decline.",
            "detection_performance": "Table summary (aggregate): machine learning methods sensitivity ~80–90% and specificity ~85–90% in cited studies/reviews—performance depends on input data quality, task, and cross-validation methods. Stage: applied to detect early functional/structural changes and to aid early/prodromal detection when combined with biomarkers.",
            "study_type": "review citing algorithm development studies, systematic reviews of ML in imaging",
            "study_population": "Datasets include research cohorts with imaging and biomarker data (e.g., ADNI and similar cohorts) used for algorithm training and testing; heterogeneity across studies.",
            "controversies_or_limitations": "Challenges include data quality, small sample sizes, lack of external validation, interpretability of models, biases in training data, and need for standardization for clinical deployment.",
            "uuid": "e9991.10",
            "source_info": {
                "paper_title": "Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations",
                "publication_date_yy_mm": "2023-09"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to",
            "rating": 2,
            "sanitized_title": "the_amyloid_hypothesis_of_alzheimers_disease_progress_and_problems_on_the_road_to"
        },
        {
            "paper_title": "High performance plasma amyloid-β biomarkers for Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "high_performance_plasma_amyloidβ_biomarkers_for_alzheimers_disease"
        },
        {
            "paper_title": "Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography",
            "rating": 2,
            "sanitized_title": "plasma_phosphotau181_increases_with_alzheimers_disease_clinical_severity_and_is_associated_with_tauand_amyloidpositron_emission_tomography"
        },
        {
            "paper_title": "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease",
            "rating": 2,
            "sanitized_title": "cerebrospinal_fluid_and_plasma_biomarkers_in_alzheimer_disease"
        },
        {
            "paper_title": "Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis",
            "rating": 2,
            "sanitized_title": "prevalence_of_cerebral_amyloid_pathology_in_persons_without_dementia_a_metaanalysis"
        },
        {
            "paper_title": "Imaging beta-amyloid burden in aging and dementia",
            "rating": 2,
            "sanitized_title": "imaging_betaamyloid_burden_in_aging_and_dementia"
        },
        {
            "paper_title": "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "serum_neurofilament_dynamics_predicts_neurodegeneration_and_clinical_progression_in_presymptomatic_alzheimers_disease"
        }
    ],
    "cost": 0.0199645,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations
09/09/2023</p>
<p>Anup Juganavar anupjuganavar9003@gmail.com 
Abhishek Joshi 
Tejas Shegekar </p>
<p>Jawaharlal Nehru Medical College
Datta Meghe Institute of Higher Education and Research
WardhaIND</p>
<p>Community Medicine
Jawaharlal Nehru Medical College
Datta Meghe Institute of Higher Education and Research
WardhaIND</p>
<p>Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations
09/09/202347218E69FF0AE9B1BAF7105E61802AE010.7759/cureus.44937Received 08/09/2023 Review began 08/12/2023 Review ended 09/04/2023Internal MedicinePathologyRadiology biomarkersdiagnostic toolsmachine learning techniqueneuroimaging techniqueslipid biopsyalzheimer's disease
The hunt for early Alzheimer's disease detection has created cutting-edge diagnostic instruments with enormous promise.This article examines the many facets of these developments, focusing on how they have revolutionised diagnosis and patient outcomes.These tools make it possible to detect tiny brain changes even before they give birth to clinical symptoms by combining cutting-edge biomarkers, neuroimaging methods, and machine-learning algorithms.A significant opportunity for therapies that can slow the course of the disease exists during this early detection stage.Additionally, these cutting-edge techniques improve diagnostic precision, objectivity, and accessibility.Liquid biopsies and blood-based biomarkers provide noninvasive alternatives, filling accessibility gaps in diagnosis.While issues with standardisation, ethics, and data integration continue, collaboration within research, clinical practice, and policy realms fuels positive developments.As technology advances, the way towards better Alzheimer's diagnosis becomes more evident, giving patients and families dealing with this difficult illness fresh hope.The synergy between scientific advancement and compassionate treatment is crucial for improving Alzheimer's disease diagnosis, as this paper emphasises.</p>
<p>Introduction And Background</p>
<p>Alzheimer's is a common neurodegenerative condition marked by a slow loss of cognitive function and memory.It accounts for 60-80% of dementia cases, making it the most likely cause of dementia.The disease typically affects older persons, with the risk dramatically rising beyond 65 years [1].Amyloid plaques and neurofibrillary tangles build up in the brain in Alzheimer's disease, resulting in the death of neurons and malfunctioning synapses [2].Cognitive deficiencies, behavioural issues, and functional impairment brought on by these pathological changes significantly negatively influence the quality of life of the affected person and their carers.</p>
<p>The importance of early Alzheimer's disease identification cannot be overstated for several convincing reasons.To start with, early detection enables sufferers and their families to make plans and get ready for the future.It allows one to make thoughtful choices about financial, legal, and medical issues, ensuring the necessary support systems are in place.Second, early identification makes it easier to obtain various therapies and interventions that might halt the spread of the illness or lessen symptoms.Even though there is currently no cure for Alzheimer's, several drugs and treatment techniques can help control symptoms and improve general well-being.Additionally, early diagnosis makes it possible for people to participate in clinical trials and research projects meant to provide cutting-edge cures or preventative measures.People in the early stages of the disease are frequently needed for this research, and their involvement can significantly advance scientific knowledge and lead to treatment advances [1].</p>
<p>To diagnose Alzheimer's disease early, diagnostic techniques are essential.They help medical practitioners identify cognitive impairment, differentiate Alzheimer's disease from other types of dementia, and track the course of the disease.Creating and using trustworthy diagnostic tools is essential for increasing diagnostic precision, decreasing misdiagnosis rates, and permitting prompt action.The creation of diagnostic techniques for Alzheimer's disease has advanced significantly over time.Traditional approaches have been the cornerstone of diagnosis, including clinical examination, medical history assessment, cognitive testing, and brain imaging techniques [2].These techniques have drawbacks, such as late-stage findings, subjectivity, and invasive methods.Recent developments in neuroimaging methods, biomarkers, and machine learning algorithms have created novel opportunities for early detection and increased diagnostic precision [3].The emergence of the newest diagnostic techniques has the potential to transform the process of early detection of Alzheimer's disease completely.It might revolutionize clinical practice, improve patient care, and accelerate the development of new treatment procedures and preventative measures.</p>
<p>Review Methodology</p>
<p>To ensure a comprehensive exploration of diagnostic tools for early Alzheimer's disease detection, a systematic search was executed.The search was conducted in prominent databases, including PubMed, Scopus, and Web of Science, on 19 July 2023.The search utilised relevant keywords and Medical Subject Headings (MeSH) terms encompassing Alzheimer's disease, early detection, diagnostic tools, biomarkers, neuroimaging, and machine learning.The study selection adhered to predetermined criteria, focusing on studies directly related to innovative diagnostic tools for early Alzheimer's detection.Non-English studies, non-peer-reviewed articles, and those focused primarily on other neurodegenerative disorders were excluded.The initial search yielded 73 articles, and after removing duplicates, a two-phase screening process led to 68 articles for full-text review.Ultimately, 59 studies were incorporated into the final review.For visual clarity, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram (Figure 1) below succinctly depicts the article selection process.</p>
<p>Traditional diagnostic methods for Alzheimer's disease</p>
<p>Clinical Evaluation and Medical History</p>
<p>Examining the patient's clinical condition and medical history are essential steps in diagnosing Alzheimer's disease.To learn about the patient's complaints, history of illness, and cognitive impairment, healthcare experts interview patients and their carers in-depth [4].They evaluate several things, including behavioural and functional limitations and changes in memory, language, thinking, and problem-solving skills [5].During the clinical examination, doctors may use standardised instruments to evaluate cognitive function and review for dementia, such as the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) [6].These assessments gauge a patient's cognitive ability by measuring their memory, attention, language, and visuospatial skills.During the medical history evaluation, details on the patient's current and historical health issues, usage of medications, and family history of dementia are gathered [7].A thorough medical history is necessary for a definitive diagnosis of Alzheimer's disease since other medical disorders and drugs can cause cognitive impairment or mimic its symptoms [8].</p>
<p>Brain Imaging Techniques</p>
<p>Techniques for imaging the brain are essential in diagnosing Alzheimer's disease.They help identify important disease-related biomarkers by offering insightful information on the structural and functional alterations happening in the brain [9].</p>
<p>An in-depth brain anatomy image is produced using the non-invasive imaging method known as magnetic resonance imaging (MRI).Healthcare practitioners may analyse brain shrinkage, spot anomalies, and spot structural changes linked to Alzheimer's disease because of the high-resolution pictures it gives [10].An Alzheimer's diagnosis can be supported by MRI results, which may help rule out alternative causes of cognitive impairment.The characteristic pathology of Alzheimer's disease, i.e., beta-amyloid plaques and neurofibrillary tangles, may be seen with PET scans [11].Numerous PET tracers have been designed, including florbetapir, flutemetamol, and florbetaben, to visualise and measure the amount of beta-amyloid plaques in the brain, assisting in the identification and differential diagnosis of Alzheimer's disease [12].</p>
<p>Single-photon emission computed tomography (SPECT) imaging can reveal essential details regarding regional brain function and illustrate regions with decreased blood flow or aberrant metabolism [13].In addition to assisting in the early diagnosis and tracking of the illness's course, SPECT scans can distinguish Alzheimer's disease from other forms of dementia.An understanding of brain activity and functional connectivity may be gained by functional magnetic resonance imaging (fMRI), which tracks changes in cerebral blood flow and oxygenation levels in the brain.It can assist in locating anomalies in neural networks and evaluating the functional limitations brought on by Alzheimer's disease [14].Understanding illness processes and cognitive decline, fMRI is especially helpful in examining the brain's functional alterations during cognitive activities and resting-state situations.</p>
<p>Cognitive Assessments</p>
<p>Diagnosing Alzheimer's disease and determining the degree of cognitive impairment depend heavily on cognitive exams.These tests offer quantifiable measurements of cognitive performance in various areas, assisting in identifying particular impairments and monitoring long-term improvements [15].MMSE is a frequently employed cognitive screening measure that evaluates several cognitive domains, including orientation, attention, memory, language, and visual-spatial abilities [6].A sequence of questions and exercises, including word recall, counting backwards, and obeying instructions, make up the test.A total score between 0 and 30 is possible; lower values denote more severe cognitive impairment.Compared to the MMSE, the MoCA is another often-used cognitive screening instrument offering a more thorough cognitive function assessment.Additionally, it evaluates executive skills, visuospatial skills, and attention to detail [16].Higher overall scores, which range from 0 to 30, indicate superior cognitive function.</p>
<p>A more thorough cognitive evaluation instrument created especially for Alzheimer's disease clinical trials is the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog).It assesses several areas of cognition, such as memory, language, praxis, and orientation [17].The ADAS-Cog comprises several tasks and questions; depending on the version taken, there are different score ranges.The clinical dementia rating (CDR) is a thorough evaluation instrument that rates cognitive and functional abilities across several categories.It comprises interviews with the patient and an informant (such as a family member or carer) and assigns a score of 0-5 to cognitive impairment.The CDR assists in assessing the degree of dementia and offers a comprehensive evaluation of cognitive function [18].</p>
<p>Limitations of traditional diagnostic methods</p>
<p>Late-Stage Detection</p>
<p>Conventional diagnostic techniques for Alzheimer's disease tend to identify the condition only after severe neurodegeneration and cognitive impairment, which is one of its significant drawbacks.A diagnosis can be delayed due to relying too heavily on clinical assessments, medical history evaluations, and cognitive testing, missing out on possibilities for early intervention and treatment [19].The treatment of the disease and the potential advantages of therapeutic approaches are complicated by late-stage identification.The brain may already be irreparably damaged by the time symptoms emerge and a diagnosis is obtained.Early identification is essential because it enables the application of prompt therapies and tactics to slow the course of illness and enhance patient outcomes [3].</p>
<p>Subjectivity and Variability</p>
<p>The inherent subjectivity and inconsistency in the comprehension of clinical evaluations and cognitive tests is another drawback of conventional diagnostic techniques for Alzheimer's disease.These techniques rely significantly on the professional opinion and knowledge of medical experts, which raises the possibility of inter-rater variability and subjective biases [20].Patient's symptoms and functional limitations are prone to subjective judgements during clinical examinations like interviews and observations.Due to healthcare practitioners' diverse degrees of knowledge and interpretative abilities, conflicting diagnoses and treatment suggestions may result [21].Particularly in its early stages, when symptoms may be modest, the subjectivity and unpredictability of conventional diagnostic techniques can make it difficult to accurately and reliably diagnose Alzheimer's disease.It highlights the requirement for more impartial, quantitative diagnostic instruments that can deliver reliable outcomes.</p>
<p>Expensive and Invasive Procedures</p>
<p>Conventional diagnostic techniques for Alzheimer's disease sometimes entail pricy, intrusive procedures that might be difficult to access, costly, and unpopular with patients.The brain imaging techniques for Alzheimer's include MRI, PET, and SPECT.However, these methods may be expensive and require specialised tools and skilled staff [10][11][12][13]22].Additionally, introducing radioactive tracers may be necessary for some imaging procedures, which can be hazardous and logistically challenging.A thorough evaluation of cognitive function may be obtained by neuropsychological testing; however, doing so often takes time, knowledge, and specialised tools.These tests are expensive and less available in some healthcare settings since they frequently require neuropsychologists or other specialised professionals for administration and interpretation [23].When it comes to the existence of specific biomarkers linked to Alzheimer's disease, including beta-amyloid and tau proteins, CSF examination can offer helpful information.However, getting CSF samples necessitates lumbar puncture, an intrusive procedure with potential dangers [24].Furthermore, most CSF analyses are carried out in specialised labs, raising costs and logistical difficulties.</p>
<p>Advancements in diagnostic tools for early detection</p>
<p>Biomarkers and Cerebrospinal Fluid Analysis</p>
<p>The use of biomarkers, notably through CSF examination, has been a focus of recent developments in diagnostic methods for the early diagnosis of Alzheimer's disease.These biomarkers allow for the identification of those at risk or who are just beginning to develop the disease, and they also offer important insights into the underlying pathological processes [25].The proteins tau and beta-amyloid are important indicators linked to Alzheimer's disease.The disease's distinguishing characteristics include aberrant tau protein phosphorylation and increased amounts of beta-amyloid in the brain [26].The measurement of beta-amyloid (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) proteins in CSF might provide critical diagnostic data [27].The usefulness of CSF biomarkers in distinguishing people with Alzheimer's disease from healthy controls and those with other kinds of dementia has been shown in several studies [28].Alzheimer's pathology has been linked to decreased levels of Aβ42 and elevated levels of t-tau and p-tau in the CSF, which may be beneficial in the early identification of the disease [29].More biomarkers are being researched to diagnose Alzheimer's disease early.Among these are indicators of vascular abnormalities, synaptic dysfunction, neurodegeneration, and neuroinflammatory markers [30].For instance, the neurofilament light chain (NfL) has demonstrated potential as a marker of neurodegeneration and the development of illness [31].</p>
<p>Targeted Positron Emission Tomography (PET) Imaging</p>
<p>A sophisticated diagnostic method that has shown tremendous promise in the early diagnosis of Alzheimer's disease is PET imaging.It enables the visualisation and measurement of specific molecular processes in the brain, revealing important details about the disease's underlying pathophysiology [32].For the early identification of beta-amyloid plaques, one of the indicators of Alzheimer's disease, amyloid PET imaging is beneficial.In the brain, beta-amyloid aggregates are mainly bound by radiotracers such as Pittsburgh compound B (PiB), florbetapir, florbetaben, and flutemetamol [33].Amyloid PET imaging aids in the early detection of patients with Alzheimer's disease by displaying the location and buildup of beta-amyloid.According to studies, amyloid PET imaging can help differentiate between people with Alzheimer's disease and people with other kinds of dementia or healthy controls [34].It has shown great sensitivity and specificity in identifying beta-amyloid deposition, allowing for precise diagnosis and better patient treatment [35].Tau PET imaging is another emerging application of PET technology in Alzheimer's disease diagnosis.Radiotracers such as 18F-AV-1451 (also known as T807 or flortaucipir) and 18F-MK-6240 selectively bind to tau protein aggregates, which are associated with neurofibrillary tangles in the brain.Tau pathology may be seen and quantified by tau PET imaging, which adds to our understanding of the course and severity of the illness.Alzheimer's disease can be distinguished from other neurodegenerative conditions using tau PET imaging, which has shown promise in identifying tau damage in people [36].</p>
<p>Blood-Based Biomarkers and Liquid Biopsies</p>
<p>The creation of liquid biopsies and blood-based biomarkers as non-invasive diagnostic methods for the early diagnosis of Alzheimer's disease has garnered growing interest in recent years.When compared to invasive treatments like CSF analysis or neuroimaging techniques, these methods have the benefit of being easily accessible and perhaps being less expensive.</p>
<p>There have been studies on several putative blood-based biomarkers.A number of amyloid-beta (Aβ) peptides, notably Aβ42 and Aβ40, have been investigated as blood-based biomarkers for Alzheimer's disease [37].Changes in the ratios or concentrations of these peptides in the blood may indicate an underlying amyloid condition.The production of neurofibrillary tangles in Alzheimer's disease is thought to be influenced by tau proteins, particularly phosphorylated versions (p-tau).Total tau or p-tau blood-based tests have demonstrated potential in identifying Alzheimer's disease [38].When neurons are damaged or degenerate, a protein called NfL that is present in neurons is released into the circulation.Increased NfL levels have been linked to neurodegenerative conditions such as Alzheimer's disease [39].Blood-based NfL tests are a possible indicator of illness advancement and therapeutic response.</p>
<p>Biomarkers in bodily fluids such as blood, saliva, urine, and CSF are analysed during liquid biopsies.They provide a simple, accessible method for identifying the molecular alterations linked to Alzheimer's disease.Blood samples with circulating cell-free DNA or RNA can be examined to learn about genetic or epigenetic changes particular to a specific illness [40].Potential biomarkers for Alzheimer's may include changes in certain genes or gene expression patterns.Exosomes may be separated from different bodily fluids and then examined for disease-specific indicators.Exosomal biomarkers have demonstrated potential in the early diagnosis and follow-up of neurodegenerative illnesses, including Alzheimer's disease [41].</p>
<p>Neuroimaging Techniques and Machine Learning Algorithms</p>
<p>Machine learning algorithms paired with neuroimaging methods have become effective tools for the early identification and diagnosis of Alzheimer's disease.These methods use neuroimaging's capacity to record structural, functional, and chemical changes in the brain.At the same time, machine learning techniques make it possible to analyse and comprehend intricate patterns in imaging data.An understanding of functional brain activity may be gained by fMRI, which tracks variations in blood oxygenation levels in the brain.It is able to spot changes in connectivity and activity patterns linked to Alzheimer's disease [42].Complex functional connectivity networks may be analysed using machine learning algorithms applied to fMRI data to find biomarkers that distinguish people with Alzheimer's disease from healthy controls.For instance, early functional connectivity abnormalities in Alzheimer's disease have shown promise when detected using graph-based methods in conjunction with support vector machine classifiers [43].</p>
<p>Benefits of new diagnostic tools</p>
<p>Early Identification of Alzheimer's Disease</p>
<p>There are several advantages to developing new diagnostic methods for the early diagnosis of Alzheimer's disease.Early detection enables prompt intervention and therapy, which may halt the course of the disease and enhance patient outcomes.Identifying small changes in the brain may be done using biomarkers, neuroimaging, and machine-learning techniques even before clinical symptoms appear [44].This early detection helps to focus therapies at the prodromal or preclinical periods, when they may be most successful.</p>
<p>Improved Accuracy and Objectivity</p>
<p>The new diagnostic tools use cutting-edge technology and quantitative techniques, improving the objectivity and accuracy of Alzheimer's disease diagnosis.Combining machine learning algorithms with biomarkers like beta-amyloid and tau in blood or CSF enhances the accuracy of diagnosis [45].This lessens the dependence on arbitrary clinical judgements, reducing the variation in diagnosis across various healthcare experts.</p>
<p>Non-invasive and Cost-Effective Procedures</p>
<p>There are several advantages to non-invasive diagnostic techniques, including liquid biopsies and bloodbased biomarkers.These techniques are less intrusive than more established ones like PET scans or lumbar punctures, lessening the patient's danger and pain [39].Additionally, liquid biopsies and blood-based biomarkers are more affordable and practical, enabling a larger population to receive early Alzheimer's diagnosis.</p>
<p>Facilitating Early Intervention and Treatment</p>
<p>With the rising idea of precision medicine, the availability of new diagnostic technologies allows early intervention and treatment techniques.Early detection enables medical professionals to customise therapies to specific patients depending on each patient's illness stage and features [3].This personalised strategy improves the efficacy of disease-modifying treatments and raises the chance of successful treatment results.</p>
<p>A comparison of Alzheimer's disease diagnostic tools is summarised in Table 1 [10,18,32,37,44,[46][47][48][49][50][51][52][53][54].</p>
<p>Challenges and future directions</p>
<p>Standardisation and Validation of Diagnostic Tests</p>
<p>New diagnostic procedures for Alzheimer's disease have difficulties with standardisation and validation.As more and more biomarkers, imaging methods, and machine learning algorithms are researched, it becomes increasingly important to guarantee accurate findings in various contexts.The widespread clinical application of these techniques is hampered by the absence of standardised methods for sample collection, processing, and interpretation [54].Another difficulty is confirming the validity of diagnostic tests' clinical value and accuracy.The sensitivity, specificity, and predictive usefulness of new instruments must be established through extensive longitudinal research.Developing a solid evidence basis also depends on harmonising findings from research teams and clinical locations [55].</p>
<p>Accessibility and Affordability</p>
<p>While modern diagnostic technologies show promise, it is essential to ensure they are affordable and accessible to various people.Advanced neuroimaging methods, such as targeted PET scans, can be costly and require specialised equipment and skills [56].Although liquid biopsies and blood-based biomarkers are more widely available options, their use necessitates the creation of accurate, affordable assays that can be quickly incorporated into standard clinical practice.For these innovative procedures to be widely used, insurance coverage and reimbursement challenges must be addressed [57].</p>
<p>Integration of Multiple Diagnostic Approaches</p>
<p>Integrating various methodologies brings possibilities and problems as diagnostic tools develop.Integrating biomarkers, neuroimaging, and machine learning algorithms can improve diagnostic precision, but it is crucial to consider the complexities of interpreting multimodal data [58].Creating algorithms that combine data from diverse sources and yield therapeutically beneficial findings is challenging.To achieve consistent and understandable results across research and clinical contexts, standardising techniques for integrating various diagnostic modalities is crucial [59].</p>
<p>Conclusions</p>
<p>Advanced diagnostic methods are essential for the early diagnosis of Alzheimer's disease.These methods, which combine machine learning, neuroimaging, and biomarkers, enable the detection of minor brain alterations even before symptoms appear.Early illness stages offer a critical opportunity for therapies that may slow the course of the disease.These methods improve diagnostic objectivity and accuracy while introducing more affordable and accessible choices, including blood-based biomarkers and liquid biopsies.The cooperation between researchers, physicians, and policymakers promises a bright future even though issues with standardisation, accessibility, ethics, and data integration still exist.As science and technology develop, the road to a better Alzheimer's diagnosis becomes clearer, giving patients and their families fresh hope as they deal with the difficulties of this illness.</p>
<p>FIGURE 1 :
1
FIGURE 1: The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram illustrating the process of study selection</p>
<p>tool Type Traditional/novel Sensitivity range Specificity range Advantages Challenges
Brain imaging techniquesNeuroimaging TraditionalPET (amyloid): 70-90%, MRI: 85%PET (amyloid): 90-95%, MRI: variedMolecular insightsHigh cost, radiation exposureCognitive assessmentClinicalTraditional60-85%70-85%Patient history insightsSubjectivity, cultural biasCSF analysisBiomarkersNovel85-90%90-95%Disease-specificInvasive, discomfortMachine learningAlgorithm-basedNovel80-90%85-90%Data pattern recognitionData quality, interpretabilityBlood-based markersBiomarkersNovel70-80%80-90%Non-invasive early stage diagnosisValidation, variability
2023 Juganavar et al.Cureus 15(9): e44937.DOI 10.7759/cureus.449375 of 8 Diagnostic</p>
<p>TABLE 1 : Comparison of Alzheimer's disease diagnostic tools
1
PET: positron emission tomography; CSF: cerebrospinal fluid.The table has been created by the authors.</p>
<p>Juganavar et al. Cureus 15(9): e44937. DOI 10.7759/cureus.44937
Additional Information DisclosuresConflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
What is Alzheimer's disease?. 2023. August 10, 2023</p>
<p>Alzheimer's disease: the challenge of the second century. D M Holtzman, J C Morris, A M Goate, 10.1126/scitranslmed.3002369?utm_medium=email&amp;utm_source=transactionSci Transl Med. 32011</p>
<p>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. R A Sperling, P S Aisen, L A Beckett, 10.1016/j.jalz.2011.03.003?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 72011</p>
<p>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. G M Mckhann, D S Knopman, H Chertkow, 10.1016/j.jalz.2011.03.005?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 72011</p>
<p>Practice parameter: diagnosis of dementia (an evidencebased review. D S Knopman, S T Dekosky, J L Cummings, 10.1212/wnl.56.9.1143?utm_medium=email&amp;utm_source=transactionReport of the Quality Standards Subcommittee of the American Academy of Neurology. 200156</p>
<p>A practical method for grading the cognitive state of patients for the clinician. M F Folstein, S E Folstein, P R Mchugh, 10.1016/0022-3956(75)90026-6?utm_medium=email&amp;utm_source=transactionJ Psychiatr Res. 121975Mini-mental state</p>
<p>The AD8: a brief informant interview to detect dementia. J E Galvin, C M Roe, K K Powlishta, 10.1212/01.wnl.0000172958.95282.2a?utm_medium=email&amp;utm_source=transactionNeurology. 652005</p>
<p>Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). R C Petersen, J C Stevens, M Ganguli, E G Tangalos, J L Cummings, S T Dekosky, 10.1212/wnl.56.9.1133?utm_medium=email&amp;utm_source=transactionReport of the Quality Standards Subcommittee of the American Academy of Neurology. 200156</p>
<p>Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond. H Hampel, S Lista, S J Teipel, 10.1016/j.bcp.2013.11.009?utm_medium=email&amp;utm_source=transactionBiochem Pharmacol. 882020. 2014</p>
<p>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Jack CrJr, D S Knopman, W J Jagust, 10.1016/S1474-4422(09)70299-6?utm_medium=email&amp;utm_source=transactionLancet Neurol. 92010</p>
<p>Imaging beta-amyloid burden in aging and dementia. C C Rowe, S Ng, U Ackermann, 10.1212/01.wnl.0000261919.22630.ea?utm_medium=email&amp;utm_source=transactionNeurology. 682007</p>
<p>18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. R Vandenberghe, K Van Laere, A Ivanoiu, 10.1002/ana.22068?utm_medium=email&amp;utm_source=transactionAnn Neurol. 682010</p>
<p>Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. J T O'brien, S Colloby, J Fenwick, 10.1001/archneur.61.6.919?utm_medium=email&amp;utm_source=transactionArch Neurol. 612004</p>
<p>APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. Y I Sheline, J C Morris, A Z Snyder, 10.1523/JNEUROSCI.3987-10.2010?utm_medium=email&amp;utm_source=transactionJ Neurosci. 302010</p>
<p>Population-based norms for the mini-mental state examination by age and educational level. R M Crum, J C Anthony, S S Bassett, M F Folstein, 10.1001/jama.1993.03500180078038?utm_medium=email&amp;utm_source=transactionJAMA. 121993</p>
<p>MoCA: a brief screening tool for mild cognitive impairment. Z S Nasreddine, N A Phillips, V Bédirian, 10.1111/j.1532-5415.2005.53221.x?utm_medium=email&amp;utm_source=transactionThe Montreal Cognitive Assessment. 200553</p>
<p>A new rating scale for Alzheimer's disease. W G Rosen, R C Mohs, K L Davis, 10.1176/ajp.141.11.1356?utm_medium=email&amp;utm_source=transactionAm J Psychiatry. 1411984</p>
<p>Diagnosis and treatment of Alzheimer's disease: an update. E Bomasang-Layno, R Bronsther, 10.32481/djph.2021.09.009?utm_medium=email&amp;utm_source=transactionDela J Public Health. 72021</p>
<p>The Clinical Dementia Rating (CDR): current version and scoring rules. J C Morris, 10.1212/wnl.43.11.2412-a?utm_medium=email&amp;utm_source=transactionNeurology. 1993</p>
<p>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. B Dubois, H H Feldman, C Jacova, 10.1016/S1474-4422(14)70090-0?utm_medium=email&amp;utm_source=transactionLancet Neurol. 62014</p>
<p>Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. T J Ferman, G E Smith, K Kantarci, 10.1212/01.wnl.0000436942.55281.47?utm_medium=email&amp;utm_source=transactionNeurology. 812013</p>
<p>Imaging the evolution and pathophysiology of Alzheimer disease. W Jagust, 10.1038/s41583-018-0067-3?utm_medium=email&amp;utm_source=transactionNat Rev Neurosci. 192018</p>
<p>The neuropsychological profile of Alzheimer disease . Cold Spring Harb Perspect Med. S Weintraub, A H Wicklund, D P Salmon, 10.1101/cshperspect.a006171?utm_medium=email&amp;utm_source=transaction20122</p>
<p>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. K Blennow, H Hampel, M Weiner, H Zetterberg, 10.1038/nrneurol.2010.4?utm_medium=email&amp;utm_source=transactionNat Rev Neurol. 62010</p>
<p>From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer's disease. H Zetterberg, K Blennow, 10.3233/JAD-179926?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 642018</p>
<p>Parkinson's and Lewy body dementia CSF biomarkers. L Parnetti, S Paciotti, L Farotti, G Bellomo, F N Sepe, P Eusebi, 10.1016/j.cca.2019.04.078?utm_medium=email&amp;utm_source=transactionClin Chim Acta. 4952019</p>
<p>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to. J Hardy, D J Selkoe, 10.1126/science.1072994?utm_medium=email&amp;utm_source=transaction10.1126/science.1072994Juganavar et al. Cureus. 1592023</p>
<p>Cerebrospinal fluid biomarkers for Alzheimer's disease. K Blennow, H Zetterberg, 10.3233/JAD-2009-1177?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 182009</p>
<p>CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. N Mattsson, H Zetterberg, O Hansson, 10.1001/jama.2009.1064?utm_medium=email&amp;utm_source=transactionJAMA. 3022009</p>
<p>Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. H Hampel, N Toschi, C Babiloni, 10.3233/JAD-179932?utm_medium=email&amp;utm_source=transactionJ Alzheimers Dis. 642018</p>
<p>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. O Preische, S A Schultz, A Apel, 10.1038/s41591-018-0304-3?utm_medium=email&amp;utm_source=transactionNat Med. 252019</p>
<p>Molecular and imaging biomarkers in Alzheimer's disease: a focus on recent insights. C Villa, M Lavitrano, Salvatore E Combi, R , 10.3390/jpm10030061?utm_medium=email&amp;utm_source=transactionJ Pers Med. 102020</p>
<p>Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. W E Klunk, H Engler, A Nordberg, 10.1002/ana.20009?utm_medium=email&amp;utm_source=transactionAnn Neurol. 552004</p>
<p>Amyloid imaging with PET in early Alzheimer disease diagnosis. C C Rowe, V L Villemagne, 10.1016/j.mcna.2012.12.017?utm_medium=email&amp;utm_source=transactionMed Clin North Am. 972013</p>
<p>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. W J Jansen, R Ossenkoppele, D L Knol, 10.1001/jama.2015.4668?utm_medium=email&amp;utm_source=transactionJAMA. 3132015</p>
<p>Tau PET imaging in Alzheimer's disease. N Okamura, R Harada, S Furumoto, H Arai, K Yanai, Y Kudo, 10.1007/s11910-014-0500-6?utm_medium=email&amp;utm_source=transactionCurr Neurol Neurosci Rep. 2014</p>
<p>High performance plasma amyloid-β biomarkers for Alzheimer's disease. A Nakamura, N Kaneko, V L Villemagne, 10.1038/nature25456?utm_medium=email&amp;utm_source=transactionNature. 5542018</p>
<p>Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography. M M Mielke, C E Hagen, J Xu, 10.1016/j.jalz.2018.02.013?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 142018</p>
<p>Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. N Mattsson, P S Insel, S Palmqvist, 10.15252/emmm.201606540?utm_medium=email&amp;utm_source=transactionEMBO Mol Med. 82016</p>
<p>Mitochondrial genes are altered in blood early in Alzheimer's disease. K Lunnon, A Keohane, R Pidsley, 10.1016/j.neurobiolaging.2016.12.029?utm_medium=email&amp;utm_source=transactionNeurobiol Aging. 532017</p>
<p>Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. E J Goetzl, A Boxer, J B Schwartz, E L Abner, R C Petersen, B L Miller, D Kapogiannis, 10.1212/WNL.0000000000001702?utm_medium=email&amp;utm_source=transactionNeurology. 852015</p>
<p>Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. M D Greicius, G Srivastava, A L Reiss, V Menon, 10.1073/pnas.0308627101?utm_medium=email&amp;utm_source=transactionProc Natl Acad Sci U S A. 1012004</p>
<p>Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex. C J Stam, B F Jones, G Nolte, M Breakspear, P Scheltens, 10.1093/cercor/bhj127?utm_medium=email&amp;utm_source=transaction200717</p>
<p>Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. B Dubois, H Hampel, H H Feldman, 10.1016/j.jalz.2016.02.002?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 122016</p>
<p>NIA-AA research framework: toward a biological definition of Alzheimer's disease. Jack CrJr, D A Bennett, K Blennow, 10.1016/j.jalz.2018.02.018?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 142018</p>
<p>Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. P Scheltens, D Leys, F Barkhof, 10.1136/jnnp.55.10.967?utm_medium=email&amp;utm_source=transactionJ Neurol Neurosurg Psychiatry. 551992Atrophy of medial temporal lobes on MRI in "probable</p>
<p>K Blennow, H Hampel, 10.1016/s1474-4422(03)00530-1?utm_medium=email&amp;utm_source=transactionCSF markers for incipient Alzheimer's disease. 20032</p>
<p>Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. F H Duits, P Martinez-Lage, C Paquet, 10.1016/j.jalz.2015.08.003?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 122016</p>
<p>Random forest algorithm for the classification of neuroimaging data in Alzheimer's disease: a systematic review. A Sarica, A Cerasa, A Quattrone, 10.3389/fnagi.2017.00329?utm_medium=email&amp;utm_source=transactionFront Aging Neurosci. 92017</p>
<p>Transfer learning for Alzheimer's disease through neuroimaging biomarkers: a systematic review. D Agarwal, G Marques, I De La Torre-Díez, Franco Martin, M A , García Zapiraín, B , Martín Rodríguez, F , 10.3390/s21217259?utm_medium=email&amp;utm_source=transactionSensors (Basel). 2021</p>
<p>Brain amyloid imaging. C C Rowe, V L Villemagne, 10.2967/jnumed.110.076315?utm_medium=email&amp;utm_source=transactionJ Nucl Med. 522011</p>
<p>Conceptualizing mental disorders as deviations from normative functioning. A F Marquand, S M Kia, M Zabihi, T Wolfers, J K Buitelaar, C F Beckmann, 10.1038/s41380-019-0441-1?utm_medium=email&amp;utm_source=transactionMol Psychiatry. 242019</p>
<p>Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. H Hampel, K Bürger, S J Teipel, A L Bokde, H Zetterberg, K Blennow, 10.1016/j.jalz.2007.08.006?utm_medium=email&amp;utm_source=transactionAlzheimers Dement. 42008</p>
<p>Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. N Mattsson, N C Cullen, U Andreasson, H Zetterberg, K Blennow, 10.1001/jamaneurol.2019.0765?utm_medium=email&amp;utm_source=transactionJAMA Neurol. 762019</p>
<p>Current state of Alzheimer's fluid biomarkers. J L Molinuevo, S Ayton, R Batrla, 10.1007/s00401-018-1932-x?utm_medium=email&amp;utm_source=transactionActa Neuropathol. 1362018</p>
<p>Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring. W M Van Oostveen, E C De Lange, 10.3390/ijms22042110?utm_medium=email&amp;utm_source=transactionInt J Mol Sci. 222021</p>
<p>Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. H Hampel, O' Bryant, S E Molinuevo, J L , 10.1038/s41582-018-0079-7?utm_medium=email&amp;utm_source=transactionNat Rev Neurol. 142018</p>
<p>Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. R Ossenkoppele, W J Jansen, G D Rabinovici, 10.1001/jama.2015.4669?utm_medium=email&amp;utm_source=transactionJAMA. 3132015</p>
<p>Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. E C Mormino, K V Papp, D M Rentz, 10.1016/j.jalz.2017.01.018?utm_medium=email&amp;utm_source=transaction201713</p>
<p>. 10.7759/cureus.449378of8Juganavar et al. Cureus. 159e449372023</p>            </div>
        </div>

    </div>
</body>
</html>